摘要
目的观察国产胸腺肽α1(基泰)治疗恶性肿瘤的疗效。方法将150例不同类型恶性肿瘤患者随机分为3组,基泰+化疗(A)组,日达仙+化疗(B)组和单用化疗(C)组,在相同化疗条件下进行疗效对比。结果基泰在提高CD4+/CD8+和NK细胞比值,降低化疗毒副反应,提高生活质量以及缓解晚期非小细胞肺癌(NSCLC)病情等方面疗效都优于单用化疗对照(C)组(P<0.05)。但基泰组与日达仙组之间的疗效差异无显著性(P>0.05)。结论基泰联合化疗药物治疗恶性肿瘤是安全、有效和可行的,值得进一步推广应用。
Objective To observe clinical efficacy of China-made thymosin α1 （JITAL） in treating advanced carcinoma, Methods 150 patients with different types of advanced carcinoma were divided randomly into three groups：the group A was treated with JITAL and chemotherapy, the group B was treated with ZADAXI and chemotherapy, and the group C with chemotherapy alone. The efficacy of treatment was compared with chemotherapy scheme being the same. Results The therapeutic efficacy of group A was better than that of group C（P 〈 0. 05 ）with CD4^ ＋/CD8^ ＋ and NK ceil increased, toxic side effects lowered, life quality and the condition of patients with late NSCLC improved. But the therapeutic efficacy was not different between group A and group B （P 〉 0.05 ）. Conclusion Treating advanced carcinoma with JITAL combined with chemotherapeutic drugs is safe,effective and feasible and is worthy to be popularized.
出处
《中国肿瘤临床与康复》
2006年第6期499-502,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
